活動成果

日本骨髄腫学会編:多発性骨髄腫の診療方針 第5版 文光堂、東京 2020


Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Ann Hematol. 2019 May 2. doi: 10.1007/s00277-019-03702-1. [Epub ahead of print]
論文の閲覧はこちら


Kamiya Y, Chou T, Murakami H, Handa H, Ozaki S, Shimazaki C, Fuchida SI, Okada J, Itoh J, Sugiyama S, Shimizu K. Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the Heavy/Light chain assay. Hematol Oncol. 2019 Apr 2. doi: 10.1002/hon.2611. [Epub ahead of print]


Kawamura K, Tsukada N, Kanda Y, Ikeda T, Yoshida A, Ueda Y, Ishida T, Suzuki K, Murakami H. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma. Biol Blood Marrow Transplant. 2018; 24(7): 1392-1398.


Kasamatsu T, Ozaki S, Saitoh T, Konishi J, Sunami K, Itagaki M, Asaoku H, Cho T, Handa H, Hagiwara S, Wakayama T, Negoro A, Takezako N, Harada N, Kuroda Y, Nakaseko C, Miyake T, Inoue N, Hata H, Shimazaki C, Ohno T, Kuroda J, Murayama T, Kobayashi T, Abe M, Ishida T, Nagura E, Shimizu K. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma. Hematol Oncol. 2018;36(5):792-800.


日本骨髄腫学会編:多発性骨髄腫の診療方針 第4版 文光堂、東京 2016.


Iriuchishima H, Ozaki S, Konishi J, Matsumoto M, Murayama K, Nakamura F, Yamamoto G, Handa H, Saitoh T, Nagura E, Shimizu K, Nojima Y, Murakami H.Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. Acta Haematol. 2016;135(2):113-21.


Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K.
Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ann Hematol 95(6):921-9, 2016
論文の閲覧はこちら


第39回日本骨髄腫学会学術集会の会長プロジェクト「多発性骨髄腫に関する多施設共同後方視的調査研究」は2015年9月18日付でBlood Cancer Journalに掲載されました。

Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Konishi J, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, and Shimizu K. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J 2015 (5): e349. Published online 18 September 2015
論文の閲覧はこちら


Ozaki S. * Harada T. * Saitoh T. * Shimazaki C. * Itagaki M. * Asaoku H. * Kuroda Y. * Chou T. * Yoshiki Y. * Suzuki K. * Murakami H. * Hayashi K. * Mina R. * Palumbo A. * Shimizu K. * on behalf of the Japanese Society of Myeloma and the European Myeloma Network: Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation
Acta Haematol 2014;132:211-219 (DOI:10.1159/000357394)
本論文はActa HaematologicaのEditor's Choice -- Free Accessに選ばれました。
論文の閲覧はこちら


日本骨髄腫学会編:多発性骨髄腫の診療方針 第3版 文光堂、東京 2012.

以下の活動は、日本骨髄腫研究会時代のものであり、当時の臨床研究の基準や考え方に準じて同研究会により行われたものである。


島崎 千尋、村上 博和、澤村 守夫、松田 正之、木下 朝博、畑 裕之、杉浦 勇、津下 圭太郎、名倉 英一、小杉 浩史、伊藤 淳治、清水 一之: 単クローン性γグロブリン血症における血清遊離軽鎖測定の臨床的有用性。 臨床血液 2010, 51(4), 245-252.
論文の閲覧はこちら


日本骨髄腫研究会編: 多発性骨髄腫の診療指針 第2版 文光堂、 東京、 2008


Murakami H, Handa H, Abe M, Iida S, Ishii A, Ishikawa T, Ishida T, Oota M, Ozaki S, Kosaka M, Sakai A, Sawamura M, Shimazaki C, Shimizu K, Takagi T, Hata H, Fukuhara T, Fujii H, Miyata A, Wakayama T, Takatsuki K. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol. 2007, 79(3), 234-239.
論文の閲覧はこちら


Chihiro Shimazaki, Hiroshi Fujii, Takashi Yoshida, Takaaki Chou, Miki Nishimura, Hideki Asaoku, Shuichi Miyawaki, Akihiro Ishii, Tadao Ishida, Masafumi Taniwaki, Shinsuke Iida, Toshiyuki Takagi, Kiyoshi Takatsuki: Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: Results from the Japan Myeloma Study Group. Int J Hematol 81: 342-348, 2005
論文の閲覧はこちら


Hirokazu Murakami, Hiroshi Fujii, Tohru Inaba, Chihiro Shimazaki, Sinichirou Okamoto, Akiyosi Miwa, Morio Sawamura, Masahiro Abe, Takaaki Chou, Hideki Asaoku, Yoshikazu Kitahara, Kunihiko Hayashi, Masaaki Kosaka, Atsushi Togawa, and Kiyoshi Takatsuki. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high risk multiple myeloma. Eur J Haematol 73, 169-173, 2004.
論文の閲覧はこちら


日本骨髄腫研究会編: 多発性骨髄腫の診療指針 文光堂、 東京、 2004


村上博和、半田 寛、今井浩三、金倉 譲、小坂昌明、澤村守夫、島崎千尋、鈴木憲史、石井昭広、高木敏之、谷脇雅史、戸川 敦、畑 裕之、若山聡夫、高月 清: 日本骨髄腫研究会参加施設におけるサリドマイド治療の現状と成績。 臨床血液 45: 468-472, 2004
論文の閲覧はこちら


Kazuyuki Shimizu, Eiichi Nagura and Kiyoshi Takatsuki: Management of patients with multiple myeloma in Japan: Data of 1,383 patients from 16 hospitals and 1 treatment group. Leukemia & Lymphoma 45: 2465-2469, 2004
論文の閲覧はこちら


Tsuchiya J, Murakami H, Kanoh T, Kosaka M, Sezaki T, Mikuni C, Kawato M, Takagi T, Togawa A, Isobe T, Suzuki K, Imamura Y and Takatsuki K: Ten-year survival and prognostic factors in multiple myeloma. Japan Myeloma Study Group. Brit J Haematol 87: 832-834, 1994
論文の閲覧はこちら


Yukio Imamura, Toshiyuki Takagi, Yoshihito Yawata, Susumu Nishinarita, Masaaki Kosaka, Chikara Mikuni, Kiyoshi Takatsuki, Tatsuo Sezaki, Mayumi Mori, Jun Tsuchiya, Noriharu Sato, Takashi Isobe, for the Japan Myeloma Study Group: Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Intern J Hematol 59: 113-123, 1994
論文の閲覧はこちら